Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...

Huang, B.T., Li, K.F., Wu, X.S., Zhang, F.Y. and Li, Y.P. (2025) Application and Research Advancement of Antibody-Conjugated Drugs in Non-Small Cell Lung Cancer. Journal of Biosciences and Medicines, ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with ...

Background The immune suppression mechanisms in pancreatic ductal adenocarcinoma (PDAC) remain unknown, but preclinical ...

LIN treatment decreased the expression of muscle RING-finger protein-1 (MuRF1) and Atrogin1(MAFbx) in muscle, and the activation of insulin-like growth factor-1 (IGF-1)/protein kinase B (Akt)/forkhead ...

Peggy and Charles Stephenson Cancer Center and Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, United States Peggy and Charles Stephenson Cancer ...

EGFR kinase domain mutations hyperactivate the ... been as well correlated with response to EGFR inhibitors as the PI3K–Akt pathway 158. Experience with gefitinib and erlotinib has taught ...

Our updated analyses presented at SABCS show STX-478’s low dose modification rates and increased response rate at higher doses, reflecting its high level of pathway inhibition. These studies ...

Job Offer stream No Job Offer stream You need to meet the work experience, education and language requirements. Through the EMPP, we’ll waive application and biometric fees for you and your dependants ...

Figure. Overview of current and in development antiplatelet agents. COX-1 indicates cyclooxygenase-1; GPVI, glycoprotein VI; PAR1, protease-activated receptor-1; PDE, phosphodiesterase; PDI, protein ...